Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 27, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.

Toru Imai¹, Yuki Kojima², Tatsunori Shimoi¹

¹Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Anticancer Research

|April 27, 2024

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A CRX-positive RB1-deficient bone tumour with a retinoblastoma-like DNA methylation profile.

Histopathology·2026

Same author

Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer.

Breast cancer research and treatment·2026

Same author

MUC4-Positive Fibroblastoma: Clinicopathological and Molecular Analysis of 7 Cases.

The American journal of surgical pathology·2026

Same author

Ozonated Olive Oil Attenuates Hepatic Steatosis in Obese db/db Mice: Evidence for Triacylglycerol-derived Ozonides as Key Bioactive Species.

Journal of oleo science·2026

Same author

Durable tumor control with stereotactic radiotherapy and doxorubucin-ifosfamide chemotherapy in primary intracranial sarcoma, <i>DICER1</i>-mutant: a case report.

International cancer conference journal·2026

Same author

BEND2 Immunohistochemistry as a Useful Diagnostic Marker for Astroblastomas With BEND2 Fusion.

The American journal of surgical pathology·2026

The systemic inflammation response index (SIRI) can predict trabectedin treatment effectiveness in soft tissue sarcomas (STSs). Elevated pretreatment SIRI indicates a poorer prognosis for patients with STS receiving trabectedin therapy.

Area of Science:

Oncology
Immunology
Biomarker Discovery

Background:

Trabectedin is a key treatment for advanced soft tissue sarcomas (STSs), including liposarcoma and leiomyosarcoma.
Beyond direct anti-tumor effects, trabectedin influences the tumor microenvironment's immune response.
Identifying predictive biomarkers for trabectedin efficacy is crucial for optimizing patient outcomes.

Purpose of the Study:

To investigate the predictive value of inflammatory biomarkers for trabectedin efficacy in STS patients.
To assess the association between pretreatment inflammatory markers and treatment outcomes (PFS and OS).

Main Methods:

Retrospective analysis of 101 STS patients treated with trabectedin (2016-2020).
Calculation of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI) from pre-treatment blood samples.

Keywords:

Predictive factor soft tissue sarcoma systemic inflammation response index trabectedin

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Related Experiment Videos

Last Updated: Jun 27, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Statistical analysis of overall survival (OS) and progression-free survival (PFS) in relation to biomarkers and clinical factors.

Main Results:

Elevated SIRI, NLR, PLR, LMR, and C-reactive protein (CRP) were associated with worse progression-free survival (PFS) in univariate analysis.
Multivariate analysis confirmed elevated SIRI, other histology, and CRP as predictors of poor PFS.
SIRI emerged as an independent prognostic factor for overall survival (OS) in multivariate analysis.

Conclusions:

Pretreatment SIRI is a valuable biomarker for predicting prognosis in STS patients undergoing trabectedin therapy.
SIRI can aid in stratifying patients and personalizing treatment strategies for STSs.